Limits...
Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions.

Chou CP, Huang NC, Jhuang SJ, Pan HB, Peng NJ, Cheng JT, Chen CF, Chen JJ, Chang TH - PLoS ONE (2014)

Bottom Line: Immunohistochemistry revealed UBE2C positivity in 69.4% of MC samples and 77.6% negativity in non-MC samples (p<0.0001).On RT-qPCR, 56.1% of malignant MC lesion samples showed high mRNA level of UBE2C and 80% of benign MC lesion samples showed a low level of UBE2C (p = 0.1766).Furthermore, UBE2C expression was associated with that of carcinogenic genes human epidermal growth factor receptor type 2 (HER2), cellular c-Ki-ras2 proto-oncogene (KRAS), vascular endothelial growth factor (VEGF), CXC chemokine receptor 4 (CXCR4), C-C motif chemokine 5 (CCL5), neural precursor cell expressed, developmentally downregulated 9 (NEDD9) and Ras homolog family member C (RhoC).

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan.

ABSTRACT
Ubiquitin-conjugating enzyme 2C (UBE2C) contributes to ubiquitin-mediated proteasome degradation of cell cycle progression in breast cancer. Microcalcification (MC) is the most common mammographic feature of early breast cancer. In this study, we evaluated whether UBE2C could be a tumor marker of early breast cancer with MC found on screening mammography. UBE2C protein and mRNA expression were measured in breast core biopsy pairs of MC and adjacent non-MC breast tissue from each subject. Immunohistochemistry revealed UBE2C positivity in 69.4% of MC samples and 77.6% negativity in non-MC samples (p<0.0001). On RT-qPCR, 56.1% of malignant MC lesion samples showed high mRNA level of UBE2C and 80% of benign MC lesion samples showed a low level of UBE2C (p = 0.1766). We investigated the carcinogenic role of UBE2C in MCF-7 breast cancer cells with UBE2C knockdown; UBE2C knockdown downregulated cell proliferation and activated the cellular apoptosis pathway to inhibit cell colony formation. Furthermore, UBE2C expression was associated with that of carcinogenic genes human epidermal growth factor receptor type 2 (HER2), cellular c-Ki-ras2 proto-oncogene (KRAS), vascular endothelial growth factor (VEGF), CXC chemokine receptor 4 (CXCR4), C-C motif chemokine 5 (CCL5), neural precursor cell expressed, developmentally downregulated 9 (NEDD9) and Ras homolog family member C (RhoC). UBE2C may be a marker for diagnosis of nonpalpable breast lesions but not benign or malignant tumors in mammography core biopsies. Suppression of UBE2C may be a potential therapy target in breast cancer.

Show MeSH

Related in: MedlinePlus

UBE2C mRNA expression and clinico-pathological data.(A) UBE2C relative expression in non-MC and MC tissue with normalization to the internal control HPRT. (B) The relative expression of UBE2C mRNA in pairs of non-MC and MC lesions in benign and malignant samples. (C) UBE2C fold change in mRNA expression in MC/non-MC lesions in pairs of benign and malignant samples. (D) UBE2C fold change in mRNA expression in MC/non-MC lesions in fibrocystic disease (FCD), ductal carcinoma in situ (DSIC)/lobular carcinoma in situ (LCIS) and invasive ductal carcinoma (IDC) samples. Data are mean±SEM.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3974821&req=5

pone-0093934-g002: UBE2C mRNA expression and clinico-pathological data.(A) UBE2C relative expression in non-MC and MC tissue with normalization to the internal control HPRT. (B) The relative expression of UBE2C mRNA in pairs of non-MC and MC lesions in benign and malignant samples. (C) UBE2C fold change in mRNA expression in MC/non-MC lesions in pairs of benign and malignant samples. (D) UBE2C fold change in mRNA expression in MC/non-MC lesions in fibrocystic disease (FCD), ductal carcinoma in situ (DSIC)/lobular carcinoma in situ (LCIS) and invasive ductal carcinoma (IDC) samples. Data are mean±SEM.

Mentions: We measured UBE2C mRNA expression in 55 pairs of biopsies. UBE2C expression was greater in MC than non-MC lesions (p<0.0001; Figure 2A); benign and malignant samples showed a similar pattern of high UBE2C expression in MC lesions (Figure 2B). UBE2C relative expression (MC/non-MC) was greater but not significantly in malignant than benign samples (Figure 2C). Pathology diagnosis showed similar results, with lower UBE2C expression with benign fibrocystic disease than DCIS/lobular carcinoma in situ and IDC malignant lesions (Figure 2D).


Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions.

Chou CP, Huang NC, Jhuang SJ, Pan HB, Peng NJ, Cheng JT, Chen CF, Chen JJ, Chang TH - PLoS ONE (2014)

UBE2C mRNA expression and clinico-pathological data.(A) UBE2C relative expression in non-MC and MC tissue with normalization to the internal control HPRT. (B) The relative expression of UBE2C mRNA in pairs of non-MC and MC lesions in benign and malignant samples. (C) UBE2C fold change in mRNA expression in MC/non-MC lesions in pairs of benign and malignant samples. (D) UBE2C fold change in mRNA expression in MC/non-MC lesions in fibrocystic disease (FCD), ductal carcinoma in situ (DSIC)/lobular carcinoma in situ (LCIS) and invasive ductal carcinoma (IDC) samples. Data are mean±SEM.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3974821&req=5

pone-0093934-g002: UBE2C mRNA expression and clinico-pathological data.(A) UBE2C relative expression in non-MC and MC tissue with normalization to the internal control HPRT. (B) The relative expression of UBE2C mRNA in pairs of non-MC and MC lesions in benign and malignant samples. (C) UBE2C fold change in mRNA expression in MC/non-MC lesions in pairs of benign and malignant samples. (D) UBE2C fold change in mRNA expression in MC/non-MC lesions in fibrocystic disease (FCD), ductal carcinoma in situ (DSIC)/lobular carcinoma in situ (LCIS) and invasive ductal carcinoma (IDC) samples. Data are mean±SEM.
Mentions: We measured UBE2C mRNA expression in 55 pairs of biopsies. UBE2C expression was greater in MC than non-MC lesions (p<0.0001; Figure 2A); benign and malignant samples showed a similar pattern of high UBE2C expression in MC lesions (Figure 2B). UBE2C relative expression (MC/non-MC) was greater but not significantly in malignant than benign samples (Figure 2C). Pathology diagnosis showed similar results, with lower UBE2C expression with benign fibrocystic disease than DCIS/lobular carcinoma in situ and IDC malignant lesions (Figure 2D).

Bottom Line: Immunohistochemistry revealed UBE2C positivity in 69.4% of MC samples and 77.6% negativity in non-MC samples (p<0.0001).On RT-qPCR, 56.1% of malignant MC lesion samples showed high mRNA level of UBE2C and 80% of benign MC lesion samples showed a low level of UBE2C (p = 0.1766).Furthermore, UBE2C expression was associated with that of carcinogenic genes human epidermal growth factor receptor type 2 (HER2), cellular c-Ki-ras2 proto-oncogene (KRAS), vascular endothelial growth factor (VEGF), CXC chemokine receptor 4 (CXCR4), C-C motif chemokine 5 (CCL5), neural precursor cell expressed, developmentally downregulated 9 (NEDD9) and Ras homolog family member C (RhoC).

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan.

ABSTRACT
Ubiquitin-conjugating enzyme 2C (UBE2C) contributes to ubiquitin-mediated proteasome degradation of cell cycle progression in breast cancer. Microcalcification (MC) is the most common mammographic feature of early breast cancer. In this study, we evaluated whether UBE2C could be a tumor marker of early breast cancer with MC found on screening mammography. UBE2C protein and mRNA expression were measured in breast core biopsy pairs of MC and adjacent non-MC breast tissue from each subject. Immunohistochemistry revealed UBE2C positivity in 69.4% of MC samples and 77.6% negativity in non-MC samples (p<0.0001). On RT-qPCR, 56.1% of malignant MC lesion samples showed high mRNA level of UBE2C and 80% of benign MC lesion samples showed a low level of UBE2C (p = 0.1766). We investigated the carcinogenic role of UBE2C in MCF-7 breast cancer cells with UBE2C knockdown; UBE2C knockdown downregulated cell proliferation and activated the cellular apoptosis pathway to inhibit cell colony formation. Furthermore, UBE2C expression was associated with that of carcinogenic genes human epidermal growth factor receptor type 2 (HER2), cellular c-Ki-ras2 proto-oncogene (KRAS), vascular endothelial growth factor (VEGF), CXC chemokine receptor 4 (CXCR4), C-C motif chemokine 5 (CCL5), neural precursor cell expressed, developmentally downregulated 9 (NEDD9) and Ras homolog family member C (RhoC). UBE2C may be a marker for diagnosis of nonpalpable breast lesions but not benign or malignant tumors in mammography core biopsies. Suppression of UBE2C may be a potential therapy target in breast cancer.

Show MeSH
Related in: MedlinePlus